OSU-ERβ-012: a novel ER-beta agonist for immunomodulation in chronic heart failure
TS-075258 — PROBLEM
Chronic heart failure following myocardial infarction (MI) afflicts ~6.7 million US adults and is driven by maladaptive immune activation, particularly persistent activation and proliferation of CD4+ T cells. Existing anti-inflammatory and immunomodulatory approaches have largely failed to …
- College: College
of
Medicine
(COM)
- Inventors: Bansal, Shyam; Gumina, Richard
- Licensing Officer: He, Panqing
A small-molecule USP30 inhibitor protects against doxorubicin-induced cardiomyopathy
TS-075254 — Problem
Cardiomyopathy weakens the heart muscle and impairs its ability to pump blood effectively, often leading to heart failure or sudden cardiac death. While doxorubicin remains an essential component of many cancer regimens, its use is limited by the risk of causing lethal cardiomyopathy. A maj…
- College: College
of
Medicine
(COM)
- Inventors: Sun, Nuo; Krigman, Judith; Yang, Mingchong; Zhang, Ruohan
- Licensing Officer: Willson, Christopher
CPT1a gene therapy for treating and preventing cardiovascular diseases
TS-075241 — Problem
Cardiovascular diseases (CVDs) such as heart failure, myocardial infarction, and cardiomyopathies remain leading causes of death worldwide. Notably, heart failure is the only major cardiovascular condition still increasing in prevalence. Current treatments primarily consist in managing the …
- College: College
of
Medicine
(COM)
- Inventors: Lewandowski, E. Douglas; Carley, Andrew
- Licensing Officer: Willson, Christopher
Small Molecule USP30 Inhibitors for the Treatment and Prevention of Cardiomyopathy
TS-066773 — The Need
Cardiomyopathy, a disease of the heart muscle, poses significant public health challenges due to its diverse causes, symptoms, and potential complications, including heart failure and arrhythmias. With cardiomyopathy often induced by drugs, such as anthracyclines used in chemotherapy, ther…
- College: College
of
Medicine
(COM)
- Inventors: Sun, Nuo; Krigman, Judith; Yang, Mingchong; Zhang, Ruohan
- Licensing Officer: Willson, Christopher
Gene Therapy Compositions for Treating Cardiovascular Diseases
TS-063091 — A gene therapy approach to address the specific needs
of failing hearts.
Heart failure affects over 6 million adults in the US and can lead to irreversible damage to the heart.
The Need
In the realm of cardiovascular health and the management of heart-related disorders, there exists a pressing commercial need for a technology that can effectively address the challenge…
- College: College
of
Medicine
(COM)
- Inventors: Lewandowski, E. Douglas; Carley, Andrew
- Licensing Officer: Willson, Christopher
Treating Obesity and Cardiovascular Disease Via Genetic Manipulation of Skin Tissue
TS-062096 — Using tissue nano-transfection to regulate BAT and increase 12,13-diHOME production to treat obesity, cardiovascular disease and type 2 diabetes.
Cardiovascular disease (CVD) is the leading cause of death across the US and worldwide and affects almost half of all adults in the US. CVD encompasses a number of conditions that affect the heart and vasculature. CVD can arise in response to multiple factors, including obesity. Obesity elevates the…
- College: College
of
Medicine
(COM)
- Inventors: Stanford, Kristin; Gallego Perez, Daniel; Ziolo, Mark
- Licensing Officer: Willson, Christopher
Perivascular Drug Delivery Nanoplatform for Preventing Restenosis After Open Surgery
TS-039004 — Pericelle: a nanoparticle based perivascular drug delivery system to prevent stenosis and failure in vascular reconstruction surgeries.
Imaging and re-intervention procedures, necessary to maintain open blood vessels following vascular reconstruction surgery, are expensive. For example, the cost of maintenance for an arteriovenous (AV) fistula used in hemodialysis access has been estimated at $15,000/year. In bypass and AV fistula…
- College: College
of
Medicine
(COM)
- Inventors: Kent, K. Craig; Chen, Guojun; Gong, Shaoqin; Guo, Lianwang; Shi, Xudong
- Licensing Officer: Taysavang, Panya
Biomimetic Nanoplatform to Deliver Anti-Restenotic Therapeutics
TS-036654 — A stent-free delivery platform for reducing arterial plaques.
Cardiovascular disease is the leading cause of death in the United States, resulting in more than 600,000 deaths and a significant contributor to overall healthcare costs. Over 28 million Americans are diagnosed with heart disease and contribute more than $30 billion in healthcare-related expenses. …
- College: College
of
Medicine
(COM)
- Inventors: Kent, K. Craig; Chen, Guojun; Gong, Shaoqin; Guo, Lianwang; Urabe, Go; Wang, Bowen
- Licensing Officer: Bhatti, Hamid
